诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。公司2022年年度权益分派方案为：以公司现 有总股本96,696,140股为基数，向全体股东每10股派3.000000元人民币现金，同时，以资本公积金向全 体股东每10股转增6.000000股。本次权益分派股权登记日为2023年7月6日，除权除息日为2023年7月7 日。 诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万 元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说 明书显示，该公司原拟募集资金51,328.04万元，分别用于"医药中间体项目、原料药项目及研发中心扩 建项目"和"补充流动资金"。 中国经济网北京8月14日讯诚达药业（301201）(301201.SZ)今日股价下跌，截至收盘报27.34元，跌幅 5.50%，该股目前处于破发状态。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417 ...

Group 1 - The core point of the news is that Zhonghong Medical's stock has experienced a significant decline since its IPO, currently trading at 13.51 yuan, down 2.60% [1] - Zhonghong Medical was listed on the Shenzhen Stock Exchange's ChiNext board on April 27, 2021, with an initial public offering (IPO) of 41.67 million shares at a price of 48.59 yuan per share [1] - The stock reached an all-time high of 159.80 yuan on its first trading day but has since entered a state of decline, currently trading below its IPO price [1] Group 2 - The total amount raised from the IPO was 2.025 billion yuan, with a net amount of 1.896 billion yuan after expenses, which was 1.317 billion yuan more than originally planned [1] - The initial fundraising plan aimed to raise 580 million yuan for a nitrile glove project and to supplement working capital [1] - The total issuance costs for the IPO were 128 million yuan, with Haitong Securities receiving 107 million yuan as underwriting fees [1] Group 3 - In the 2022 annual profit distribution announcement, Zhonghong Medical declared a cash dividend of 7.00 yuan per 10 shares and a capital reserve transfer of 3 shares for every 10 shares held, increasing the total share capital by 9 million shares [2] - For the 2021 annual profit distribution, the company distributed a cash dividend of 30.00 yuan per 10 shares and transferred 8 shares for every 10 shares held, increasing the total share capital by 13.33 million shares [2] - A future dividend plan for 2025 includes a cash distribution of 2.5 yuan per 10 shares and a transfer of 1 share for every 10 shares held, with the ex-dividend date set for June 27, 2025 [2]

Core Viewpoint - The company, Jiemite (300868.SZ), announced a share reduction plan involving several shareholders, which may impact the stock's market performance but will not change the company's control or significantly affect its ongoing operations [1][4]. Shareholder Reduction Plans - Huang Xin, holding 7,674,336 shares (6% of total shares), plans to reduce his holdings by 1,240,000 shares (0.978%) within three months after the announcement [1]. - Yang Shaoxu, with 415,500 shares (0.325%), intends to reduce his holdings by 415,500 shares (0.328%) in the same timeframe [1]. - Liu Hui, holding 6,900 shares (0.005%), plans to reduce by 6,900 shares (0.005%) [2]. - Li Yun, with 1,039 shares (0.001%), aims to reduce by 1,039 shares (0.001%) [2]. - Bian Erli, holding 18,397 shares (0.014%), plans to reduce by 18,397 shares (0.015%) [2]. - Chen Guangping, with 215,000 shares (0.168%), intends to reduce by 215,000 shares (0.170%) [3]. - Liu Shuwei, holding 34,297 shares (0.027%), plans to reduce by 8,500 shares (0.007%) [3]. - In total, the seven shareholders hold 8,365,469 shares and plan to reduce 1,905,336 shares, accounting for 1.504% of total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being -116 million, -91.62 million, 707,000, and 7.07 million respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - The net profit attributable to shareholders for 2023 was -91.62 million, while the net profit excluding non-recurring items was 133.35 million, indicating a significant recovery from previous losses [8]. - In the first quarter of 2025, the company reported a revenue of 150 million, a decline of 29.10% year-on-year, with a net profit of -3.66 million [9].

Core Viewpoint - The company Jiemite (300868.SZ) announced a share reduction plan involving several shareholders, which will not affect the company's control or ongoing operations significantly [1][4][5]. Shareholder Reduction Plans - Shareholder Huang Xin plans to reduce holdings by 1,240,000 shares, representing 0.978% of the total shares after excluding repurchased shares [1][4]. - Shareholder Yang Shaoxu intends to reduce holdings by 415,500 shares, accounting for 0.328% of the total shares after excluding repurchased shares [1][2]. - Other shareholders, including Liu Hui, Li Yun, Bian Erli, Chen Guangping, and Liu Shuwei, also have plans to reduce their holdings, with total planned reductions amounting to 1,905,336 shares, or 1.504% of the total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being 28.22 million, -116 million, -91.62 million, and 707,000 respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - In 2024, the company expects a revenue increase to approximately 761.64 million, reflecting a 12.59% growth compared to 2023 [9]. Company Background - Jiemite was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering price of 41.26 yuan per share, raising a net amount of approximately 118.97 million yuan [6]. - The company has faced challenges, with its stock currently trading below its initial offering price, indicating a state of underperformance [6].

Group 1 - Zhongyi Technology (301150) closed at 25.57 yuan, with a decline of 5.16% [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on April 21, 2022, with an initial public offering (IPO) of 16.837 million shares at a price of 163.56 yuan per share [1] - The total funds raised from the IPO amounted to 2.754 billion yuan, with a net amount of 2.603 billion yuan, exceeding the original plan by 1.887 billion yuan [1] Group 2 - In June 2022, the company announced a cash dividend of 20 yuan per 10 shares, totaling 134.69 million yuan, and a stock bonus of 5 shares for every 10 shares held, increasing the total share capital to 101.02 million shares [2] - In June 2023, the company declared a cash dividend of 13 yuan per 10 shares, totaling 131.33 million yuan, and a stock bonus of 3 shares for every 10 shares held, raising the total share capital to 131.33 million shares [2] Group 3 - In May 2024, the company announced a dividend plan of 1 yuan per 10 shares, with a stock bonus of 4 shares for every 10 shares held [3] - In May 2025, the company revealed a dividend plan with no cash dividend, but a stock bonus of 3 shares for every 10 shares held, increasing the total share capital to 233.23 million shares [3]

Group 1 - The core point of the article highlights the current stock performance of Huasheng Lithium Battery, which has seen a decline of 5.82% to a closing price of 31.90 yuan [1] - Huasheng Lithium Battery was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 13, 2022, with an initial offering of 28 million shares at a price of 98.35 yuan per share [1] - The stock reached its highest price of 129.20 yuan on July 15, 2022, just three trading days after its listing, but is currently in a state of decline [1] - The company raised a total of 2.754 billion yuan from its initial public offering, with a net amount of 2.567 billion yuan after deducting issuance costs of 187 million yuan [1] - The net fundraising amount exceeded the original plan by 1.867 billion yuan, with the funds intended for projects including the production of 6,000 tons of vinyl carbonate and 3,000 tons of fluorinated vinyl carbonate, as well as the establishment of a research and development center [1] Group 2 - On May 10, 2023, Huasheng Lithium Battery announced a profit distribution plan, which includes a cash dividend of 1 yuan per share (tax included) and a capital reserve increase of 0.45 shares for each share held [2] - The record date for the equity distribution was set for May 9, 2023, with the ex-dividend date on May 10, 2023 [2]

长华化学上市发行募集资金总额为90,253.75万元，扣除发行费用后，募集资金净额为82,505.94万元。该 公司最终募集资金净额比原计划多52,446.44万元。长华化学于2023年7月28日披露的招股说明书显示， 其拟募集资金30,059.50万元，分别用于信息系统建设、研发中心项目、营销网络建设、补充流动资金和 偿还银行贷款。 长华化学本次发行费用总额为7,747.81万元，其中，保荐及承销费用5,184.17万元。 长华化学于2023年8月3日在深交所创业板上市，公开发行股票3,505万股，占发行后公司股份总数的比 例为25.00%，发行价格为25.75元/股，保荐人(主承销商)为东吴证券股份有限公司，保荐代表人为陈 勇、尹鹏。 中国经济网北京7月29日讯长华化学（301518）(301518.SZ)今日收报22.08元，跌幅3.07%，总市值30.95 亿元。目前该股处于破发状态。 ...

Group 1 - The core viewpoint of the news is that Suochen Technology (688507.SH) is currently experiencing a decline in stock price, with a closing price of 85.50 yuan and a drop of 2.8%, indicating a state of being below its initial public offering price [1] - Suochen Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 18, 2023, with an issuance of 10,333,400 shares at a price of 245.56 yuan per share [1] - The total amount raised from the initial public offering was 253,746.97 million yuan, with a net amount of 231,574.91 million yuan, exceeding the original plan by 134,684.55 million yuan [1] Group 2 - The total issuance costs for Suochen Technology's IPO amounted to 22,172.06 million yuan (excluding tax), with underwriting fees accounting for 19,231.02 million yuan [2] - The company announced a cash dividend of 0.15 yuan per share (including tax) and a capital reserve increase of 0.48 shares for every share held, resulting in a total distribution of 6,200,010 yuan in cash dividends and an increase of 19,840,032 shares, raising the total share capital to 61,173,432 shares [2] - For the 2023 annual profit distribution, the company plans to distribute a cash dividend of 3.80 yuan for every 10 shares (including tax) and a capital reserve increase of 4.60 shares for every 10 shares, with the record date set for June 18, 2024 [2]

Core Viewpoint - Viyuan Co., Ltd. (维远股份) has announced a significant decline in expected net profit for the first half of 2025, projecting a loss between 175 million to 165 million yuan, compared to a profit of 35.73 million yuan in the same period last year [1] Financial Performance Summary - In 2024, Viyuan Co., Ltd. reported operating revenue of 9.52 billion yuan, representing a year-on-year increase of 35.06% [3] - The net profit attributable to shareholders decreased by 42.62% to 565.89 million yuan, down from 98.62 million yuan in 2023 [3] - The net profit after deducting non-recurring gains and losses was 453.11 million yuan, a decline of 36.85% compared to 71.75 million yuan in the previous year [3] - The net cash flow from operating activities increased by 49.52% to 918.53 million yuan, compared to 613.86 million yuan in 2023 [3] Initial Public Offering (IPO) Details - Viyuan Co., Ltd. raised a total of 4.065 billion yuan through its IPO, with a net amount of 3.88 billion yuan after deducting issuance costs [4] - The final net fundraising amount exceeded the original plan by 2 billion yuan, and the number of investment projects increased by one [4] - The IPO was conducted on September 15, 2021, with an issuance price of 29.56 yuan per share, and the underwriting was managed by CITIC Securities [4]

Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]